



**Econ Healthcare (Asia) Limited  
and its subsidiaries  
Registration Number: 200400965N**

Condensed consolidated financial statements  
For the six-months period ended 30 September 2024

---

This document has been prepared by the Company and its contents have been reviewed by the Company's sponsor, R & T Corporate Services Pte. Ltd. ("Sponsor"), for compliance with the relevant rules of the Singapore Exchange Securities Trading Limited ("Exchange"). This document has not been examined or approved by the Exchange. The Exchange assumes no responsibility for the contents of this document including the correctness of any of the statements or opinions made or reports contained in this document.

The contact person for the Sponsor is Mr. Howard Cheam Heng Haw (Telephone Number: +65 6232 0685), R & T Corporate Services Pte. Ltd., at 9 Straits View #06-07, Marina One West Tower, Singapore 018937.

## Econ Healthcare (Asia) Limited and its subsidiaries

---

| <b>Table of contents</b>                                 | <b>Page</b> |
|--|-------------|
| Condensed consolidated income statement                  | 2           |
| Condensed consolidated statement of comprehensive income | 4           |
| Condensed consolidated statements of financial position  | 5           |
| Condensed consolidated statements of changes in equity   | 7           |
| Condensed consolidated statement of cash flows           | 10          |
| Notes to the condensed consolidated financial statements | 12          |
| Other information required for Half Year Announcement    | 35          |

Certain numerical figures set out in this Announcement, including financial data presented in millions or thousands and percentages, have been subject to rounding adjustments, and, as a result, the totals of the data in this Announcement may vary slightly from the actual arithmetic totals of such information. Percentages and amounts reflecting changes over time periods relating to financial and other data set forth in paragraph 4 of the section in this Announcement entitled "Other Information required for Full Year Announcement" are approximate figures and have been calculated using the numerical data in the Group's consolidated financial statements or the tabular presentation of other data (subject to rounding) contained in this Announcement, as applicable, and not using the numerical data in the narrative description thereof.

**Econ Healthcare (Asia) Limited and its subsidiaries**

**Condensed consolidated interim income statement  
For the six-months period ended 30 September 2024**

|   | Note | For the six-months period<br>ended 30 September |  | Change |
|---|------|---|--|--------|
|   |      | 2024<br>S\$'000                                 | 2023<br>S\$'000<br>(Re-<br>presented)* | %      |
| <b><u>Continuing operations</u></b>                                 |      |   |  |        |
| Revenue   | 5    | 32,743  | 24,499                                 | 33.7   |
| Other income  | 6    | 2,704   | 2,344                                  | 15.4   |
| Supplies and consumables  |      | (3,352)   | (3,260)                                | 2.8    |
| Staff costs   |      | (18,435)  | (13,602)                               | 35.5   |
| Depreciation of property, plant and equipment                       |      | (1,003)   | (639)                                  | 57.0   |
| Depreciation of right-of-use assets                                 |      | (3,787)   | (3,723)                                | 1.7    |
| Utilities expenses  |      | (802)   | (829)                                  | (3.3)  |
| Impairment losses/(reversal) on trade receivables                   |      | (24)  | 4                                      | N.M.   |
| Fair value losses on investment in quoted securities                |      | (28)  | (23)                                   | 21.7   |
| Gains on disposal of investment in quoted securities                |      | 6   | 27                                     | (77.8) |
| Other operating expenses  |      | (2,622)   | (2,200)                                | 19.2   |
|   |      | <u>5,400</u>                                    | <u>2,598</u>                           | 107.9  |
| <b>Finance costs, net</b>   | 7    | (767)   | (416)                                  | (84.4) |
| Share of loss of associate, net of tax                              |      | (139)   | –                                      | N.M.   |
| <b>Profit before tax from continuing operations</b>                 | 8    | <u>4,494</u>                                    | <u>2,182</u>                           | 106.0  |
| Tax expense   | 9    | (784)   | (344)                                  | 127.9  |
| <b>Profit for the period from continuing operations, net of tax</b> |      | <u>3,710</u>                                    | <u>1,838</u>                           | 101.8  |
| <b><u>Discontinued operations</u></b>                               |      |   |  |        |
| Loss from discontinued operations, net of tax                       |      | (126)   | (268)                                  | (53.0) |
| <b>Profit for the period</b>  |      | <u>3,584</u>                                    | <u>1,570</u>                           | 128.3  |

*N.M. – Not meaningful*

\*The comparative figures have been re-presented to report profit and loss items separately for continuing and discontinued operations.

**Econ Healthcare (Asia) Limited and its subsidiaries**

**Condensed consolidated interim income statement  
For the six-months period ended 30 September 2024**

|  | Note | For the six-months period<br>ended 30 September |                                    | Change<br>% |
|--|------|---|------------------------------------|-------------|
|  |      | 2024<br>S\$'000                                 | 2023<br>S\$'000<br>(Re-presented)* |             |
| <b>Profit attributable to:<br/>Owner of the Company</b>  |      |   |                                    |             |
| Profit from continuing operations, net of tax  |      | 3,665   | 1,867                              | 96.3        |
| Loss from discontinued operations, net of tax  |      | (91)  | (188)                              | (51.6)      |
| Profit for the period attributable to owner of the<br>Company  |      | <u>3,574</u>                                    | <u>1,679</u>                       | 112.9       |
| <b>Non-controlling interests</b>   |      |   |                                    |             |
| Profit/(loss) from continuing operations, net of<br>tax  |      | 45  | (26)                               | N.M.        |
| Loss from discontinued operations, net of tax  |      | (35)  | (83)                               | (57.8)      |
| Loss for the period attributable to non-controlling<br>interests   |      | <u>10</u>                                       | <u>(109)</u>                       | N.M.        |
| <b>Profit for the period</b>   |      | <u><u>3,584</u></u>                             | <u><u>1,570</u></u>                | 128.3       |
| <b>Earnings per share for the period from<br/>continuing operations attributable to owner<br/>of the Company</b> |      |   |                                    |             |
| Basic and diluted earnings per share (cents)   | 17   | 1.38  | 0.73                               | 89.7        |
| <b>Earnings per share</b>  |      |   |                                    |             |
| Basic and diluted earnings per share (cents)   | 17   | <u>1.34</u>                                     | <u>0.65</u>                        | 105.7       |

*N.M. – Not meaningful*

\*The comparative figures have been re-presented to report profit and loss items separately for continuing and discontinued operations.

**Econ Healthcare (Asia) Limited and its subsidiaries**

**Condensed consolidated interim statement of comprehensive income  
For the six-months period ended 30 September 2024**

|   | For the six-months period<br>ended 30 September |  | Change<br>% |
|---|---|--|-------------|
|   | 2024<br>S\$'000                                 | 2023<br>S\$'000<br>(Re-<br>presented)* |             |
| <b>Profit for the period</b>  | 3,584   | 1,570                                  | 128.3       |
| <b>Other comprehensive income</b><br><i>Items that are or may be reclassified subsequently<br/>to profit or loss:</i> |   |  |             |
| Foreign currency translation differences – foreign<br>operations  | 1,294   | (676)                                  | N.M.        |
| <b>Total comprehensive income for the period</b>  | <u>4,878</u>                                    | <u>894</u>                             | 445.6       |
| <b>Total comprehensive income attributable to:</b>  |   |  |             |
| Owner of the Company  | 5,474   | 1,170                                  | 367.9       |
| Non-controlling interests   | (596)   | (276)                                  | 115.9       |
| <b>Total comprehensive income for the period</b>  | <u>4,878</u>                                    | <u>894</u>                             | 445.6       |
| <b>Attributable to owner of the Company:</b>  |   |  |             |
| Total comprehensive income from continuing<br>operations, net of tax  | 5,484   | 1,358                                  | 303.8       |
| Total comprehensive income from discontinued<br>operations, net of tax  | (10)  | (188)                                  | (94.7)      |
| <b>Total comprehensive income for the period</b>  | <u>5,474</u>                                    | <u>1,170</u>                           | 367.9       |

*N.M. – Not meaningful*

\*The comparative figures have been re-presented to report profit and loss items separately for continuing and discontinued operations.

**Econ Healthcare (Asia) Limited and its subsidiaries**

**Condensed consolidated statements of financial position  
As at 30 September 2024**

|   | Note | Group                           |                             | Company                         |                             |
|---|------|---------------------------------|-----------------------------|---------------------------------|-----------------------------|
|   |      | 30 September<br>2024<br>S\$'000 | 31 March<br>2024<br>S\$'000 | 30 September<br>2024<br>S\$'000 | 31 March<br>2024<br>S\$'000 |
| <b>Assets</b>   |      |                                 |                             |                                 |                             |
| Property, plant and equipment   | 10   | 17,462                          | 16,578                      | 693                             | 744                         |
| Right-of-use assets   | 11   | 31,273                          | 35,051                      | 2,455                           | 2,749                       |
| Investment property   | 12   | 7,818                           | 7,177                       | –                               | –                           |
| Intangible asset  | 22   | 5,129                           | 5,129                       | –                               | –                           |
| Subsidiaries  |      | –                               | –                           | 32,640                          | 32,640                      |
| Associates  |      | 1,085                           | –                           | –                               | –                           |
| Deferred tax assets   |      | 342                             | 364                         | 175                             | 225                         |
| Trade and other receivables   | 13   | 2,617                           | 2,302                       | 3,099                           | 3,275                       |
| <b>Non-current assets</b>   |      | <b>65,726</b>                   | <b>66,601</b>               | <b>39,062</b>                   | <b>39,633</b>               |
| Inventories   |      | 1                               | 3                           | –                               | –                           |
| Current tax assets  |      | 113                             | 62                          | –                               | –                           |
| Trade and other receivables   | 13   | 12,446                          | 10,358                      | 3,436                           | 4,474                       |
| Investments in quoted securities  |      | 573                             | 1,069                       | 573                             | 1,069                       |
| Cash and short-term deposits  |      | 17,831                          | 16,181                      | 4,563                           | 4,521                       |
|   |      | 30,964                          | 27,673                      | 8,572                           | 10,064                      |
| Assets of disposal group classified as held for sale                            | 21   | –                               | 11,100                      | –                               | –                           |
| <b>Current assets</b>   |      | <b>30,964</b>                   | <b>38,773</b>               | <b>8,572</b>                    | <b>10,064</b>               |
| <b>Total assets</b>   |      | <b>96,690</b>                   | <b>105,374</b>              | <b>47,634</b>                   | <b>49,679</b>               |
| <b>Liabilities</b>  |      |                                 |                             |                                 |                             |
| Provision for restoration costs   |      | 741                             | 733                         | 84                              | 83                          |
| Deferred capital grants   |      | 2,450                           | 2,600                       | –                               | –                           |
| Deferred tax liabilities  |      | –                               | 23                          | –                               | –                           |
| Lease liabilities   |      | 26,036                          | 29,652                      | 1,646                           | 1,996                       |
| Loans and borrowings  | 18   | 1,013                           | 1,242                       | –                               | –                           |
| <b>Non-current liabilities</b>  |      | <b>30,240</b>                   | <b>34,250</b>               | <b>1,730</b>                    | <b>2,079</b>                |
| Current tax liabilities   |      | 1,237                           | 1,101                       | –                               | –                           |
| Lease liabilities   |      | 6,947                           | 7,003                       | 452                             | 467                         |
| Loans and borrowings  | 18   | 1,408                           | 2,382                       | –                               | –                           |
| Trade and other payables  | 19   | 9,167                           | 7,155                       | 2,202                           | 2,020                       |
|   |      | 18,759                          | 17,641                      | 2,654                           | 2,487                       |
| Liabilities directly associated with disposal group classified as held for sale | 21   | –                               | 8,995                       | –                               | –                           |
| <b>Current liabilities</b>  |      | <b>18,759</b>                   | <b>26,636</b>               | <b>2,654</b>                    | <b>2,487</b>                |
| <b>Total liabilities</b>  |      | <b>48,999</b>                   | <b>60,886</b>               | <b>4,384</b>                    | <b>4,566</b>                |

**Econ Healthcare (Asia) Limited and its subsidiaries**

**Condensed consolidated statements of financial position  
As at 30 September 2024**

|   | Note | Group                           |                             | Company                         |                             |
|---|------|---------------------------------|-----------------------------|---------------------------------|-----------------------------|
|   |      | 30 September<br>2024<br>S\$'000 | 31 March<br>2024<br>S\$'000 | 30 September<br>2024<br>S\$'000 | 31 March<br>2024<br>S\$'000 |
| Share capital   | 14   | 29,983                          | 29,983                      | 29,983                          | 29,983                      |
| Currency translation reserve                              | 15   | (2,978)                         | (4,704)                     | –                               | –                           |
| Merger reserve  | 15   | (99)                            | (99)                        | –                               | –                           |
| Reserves of disposal group<br>classified as held for sale | 21   | –                               | (174)                       | –                               | –                           |
| Accumulated profits                                       |      | 21,293                          | 19,394                      | 13,267                          | 15,130                      |
| <b>Equity attributable to<br/>owner of the Company</b>    |      | 48,199                          | 44,400                      | 43,250                          | 45,113                      |
| Non-controlling interests                                 |      | (508)                           | 88                          | –                               | –                           |
| <b>Total equity</b>                                       |      | 47,691                          | 44,488                      | 43,250                          | 45,113                      |
| <b>Total equity and liabilities</b>                       |      | 96,690                          | 105,374                     | 47,634                          | 49,679                      |

Econ Healthcare (Asia) Limited and its subsidiaries

Condensed consolidated interim statement of changes in equity  
For the six-months period ended 30 September 2024

| Group   | Note | Share capital<br>S\$'000 | Currency translation reserve<br>S\$'000 | Merger reserve<br>S\$'000 | Reserves of disposal group classified as held for sale<br>S\$'000 | Accumulated profits<br>S\$'000 | Total equity attributable to owner of the Company<br>S\$'000 | Non-controlling interests<br>S\$'000 | Total equity<br>S\$'000 |
|---|------|--------------------------|---|---------------------------|---|--------------------------------|--|--------------------------------------|-------------------------|
| As at 1 April 2024  |      | 29,983                   | (4,704)                                 | (99)                      | (174)   | 19,394                         | 44,400   | 88                                   | 44,488                  |
| <b>Total comprehensive income for the period</b>              |      |                          |   |                           |   |                                |  |                                      |                         |
| Profit for the period   |      | –                        | –                                       | –                         | –   | 3,574                          | 3,574  | 10                                   | 3,584                   |
| <i>Other comprehensive income</i>                             |      |                          |   |                           |   |                                |  |                                      |                         |
| Foreign currency translation differences – foreign operations |      | –                        | 1,726                                   | –                         | 174   | –                              | 1,900  | (606)                                | 1,294                   |
| <b>Total comprehensive income for the period</b>              |      | –                        | 1,726                                   | –                         | 174   | 3,574                          | 5,474  | (596)                                | 4,878                   |
| <i>Transactions with owner, recognised directly in equity</i> |      |                          |   |                           |   |                                |  |                                      |                         |
| Dividends paid  | 15   | –                        | –                                       | –                         | –   | (1,675)                        | (1,675)  | –                                    | (1,675)                 |
| Total contributions by and distribution to owner              |      | –                        | –                                       | –                         | –   | (1,675)                        | (1,675)  | –                                    | (1,675)                 |
| As at 30 September 2024                                       |      | 29,983                   | (2,978)                                 | (99)                      | –   | 21,293                         | 48,199   | (508)                                | 47,691                  |



**Econ Healthcare (Asia) Limited and its subsidiaries**

**Condensed consolidated interim statement of changes in equity  
For the six-months period ended 30 September 2023**

| <b>Group</b>   | <b>Note</b> | <b>Share capital<br/>S\$'000</b> | <b>Currency translation reserve<br/>S\$'000</b> | <b>Merger reserve<br/>S\$'000</b> | <b>Reserves of disposal group classified as held for sale<br/>S\$'000</b> | <b>Accumulated profits<br/>S\$'000</b> | <b>Total equity attributable to owner of the Company<br/>S\$'000</b> | <b>Non-controlling interests<br/>S\$'000</b> | <b>Total equity<br/>S\$'000</b> |
|--|-------------|----------------------------------|---|-----------------------------------|---|--|--|--|---------------------------------|
| As at 1 April 2023   |             | 28,255                           | (4,091)   | (99)                              | –   | 14,694                                 | 38,759   | (233)  | 38,526                          |
| <b>Total comprehensive income for the period</b>                           |             |                                  |   |                                   |   |  |  |  |                                 |
| Profit for the period  |             | –                                | –   | –                                 | –   | 1,680                                  | 1,680  | (110)  | 1,570                           |
| <i>Other comprehensive income</i>  |             |                                  |   |                                   |   |  |  |  |                                 |
| Foreign currency translation differences – foreign operations              |             | –                                | (510)   | –                                 | –   | –                                      | (510)  | (166)  | (676)                           |
| <b>Total comprehensive income for the period</b>                           |             | –                                | (510)   | –                                 | –   | 1,680                                  | 1,170  | (276)  | 894                             |
| <i>Transactions with owner, recognised directly in equity</i>              |             |                                  |   |                                   |   |  |  |  |                                 |
| Dividends paid   | 15          | –                                | –   | –                                 | –   | (1,131)                                | (1,131)  | –  | (1,131)                         |
| Capital contribution by non-controlling interests                          |             | –                                | –   | –                                 | –   | –                                      | –  | 225  | 225                             |
| Reclassification to reserves of disposal group classified as held for sale |             | –                                | 158   | –                                 | (158)   | –                                      | –  | –  | –                               |
| Total contributions by and distribution to owner                           |             | –                                | 158   | –                                 | (158)   | (1,131)                                | (1,131)  | 225  | (906)                           |
| As at 30 September 2023  |             | 28,255                           | (4,443)   | (99)                              | (158)   | 15,243                                 | 38,798   | (284)  | 38,514                          |

**Econ Healthcare (Asia) Limited and its subsidiaries**

**Condensed interim statements of changes in equity  
For the six-months period ended 30 September 2024**

| Company  | Note | Share<br>capital<br>S\$'000 | Retained<br>earnings<br>S\$'000 | Total<br>equity<br>S\$'000 |
|--|------|-----------------------------|---------------------------------|----------------------------|
| As at 1 April 2024   |      | 29,983                      | 15,130                          | 45,113                     |
| <b>Loss for the period, representing total<br/>comprehensive income for the period</b>   |      | –                           | (188)                           | (188)                      |
| <i>Transactions with owner, recognised<br/>directly in equity</i>                        |      |                             |                                 |                            |
| Dividends paid   |      | –                           | (1,675)                         | (1,675)                    |
| Total transactions with owners   |      | –                           | (1,675)                         | (1,675)                    |
| As at 30 September 2024  |      | 29,983                      | 13,267                          | 43,250                     |
| As at 1 April 2023   |      | 28,255                      | 14,503                          | 42,758                     |
| <b>Profit for the period, representing total<br/>comprehensive income for the period</b> |      | –                           | 214                             | 214                        |
| <i>Transactions with owner, recognised<br/>directly in equity</i>                        |      |                             |                                 |                            |
| Dividends paid   |      | –                           | (1,131)                         | (1,131)                    |
| Total transactions with owners   |      | –                           | (1,131)                         | (1,131)                    |
| As at 30 September 2023  |      | 28,255                      | 13,586                          | 41,841                     |

**Econ Healthcare (Asia) Limited and its subsidiaries**

**Condensed consolidated interim statement of cash flows  
For the six-months period ended 30 September 2024**

|   | Note | For the six-months period ended<br>30 September |                 |
|---|------|---|-----------------|
|   |      | 2024<br>S\$'000                                 | 2023<br>S\$'000 |
| <b>Cash flows from operating activities</b>                   |      |   |                 |
| Profit before tax from continuing operations                  |      | 4,494   | 2,182           |
| Loss before tax from discontinued operations                  |      | (126)   | (268)           |
|   |      | <u>4,368</u>                                    | <u>1,914</u>    |
| Adjustments for:  |      |   |                 |
| Amortisation of deferred capital grant                        |      | (191)   | (213)           |
| Depreciation of property, plant and equipment                 |      | 1,003   | 849             |
| Depreciation of right-of-use assets                           |      | 3,787   | 3,890           |
| Gain on termination of leases                                 |      | (7)   | –               |
| Impairment losses/(reversal) on trade receivables             |      | 24  | (4)             |
| Write-off of property, plant and equipment                    | 8    | 12  | 2               |
| Interest income   |      | (57)  | (202)           |
| Interest expense  |      | 734   | 777             |
| Unwinding of discount on provisions                           |      | 8   | 3               |
| Dividend income from investment in quoted securities          |      | (21)  | (49)            |
| Fair value losses on investment in quoted securities          |      | 28  | 23              |
| Gain on disposal of investment in quoted securities, net      |      | (6)   | (27)            |
| Impairment losses on investment in associates                 |      | 479   | –               |
| Gain on disposal of subsidiaries and associate                |      | (809)   | –               |
| Share of losses of associate                                  |      | 139   | –               |
|   |      | <u>9,491</u>                                    | <u>6,963</u>    |
| Changes in:   |      |   |                 |
| - Inventories   |      | 1   | 3               |
| - Trade and other receivables                                 |      | (2,165)   | (391)           |
| - Trade and other payables                                    |      | 2,564   | 70              |
|   |      | <u>9,891</u>                                    | <u>6,645</u>    |
| <b>Cash generated from operations</b>                         |      | <u>9,891</u>                                    | <u>6,645</u>    |
| Tax paid  |      | (693)   | (450)           |
| <b>Net cash from operating activities</b>                     |      | <u>9,198</u>                                    | <u>6,195</u>    |
| <b>Cash flows from investing activities</b>                   |      |   |                 |
| Purchase of property, plant and equipment                     |      | (1,025)   | (983)           |
| Capital grants received                                       |      | 41  | 566             |
| Interest received   |      | 50  | 162             |
| Dividend income from investment in quoted securities          | 6    | 21  | 49              |
| Investment in quoted securities                               |      | –   | (2,266)         |
| Proceeds from disposal of quoted securities                   |      | 475   | 1,905           |
| Amount refunded for acquisition of subsidiary, net            |      | 627   | –               |
| <b>Net cash generated from/(used in) investing activities</b> |      | <u>189</u>                                      | <u>(567)</u>    |
| <b>Cash flows from financing activities</b>                   |      |   |                 |
| Capital contribution by non-controlling interests             |      | –   | 225             |
| Repayment of borrowings                                       |      | (1,430)   | (817)           |
| Payment of principal portion of lease liabilities             |      | (3,839)   | (3,741)         |
| Interest paid   |      | (655)   | (779)           |
| Dividends paid  |      | (1,675)   | (1,131)         |
| <b>Net cash used in financing activities</b>                  |      | <u>(7,599)</u>                                  | <u>(6,243)</u>  |

\* Less than S\$1,000

**Econ Healthcare (Asia) Limited and its subsidiaries**

**Condensed consolidated interim statement of cash flows (cont'd)  
For the six-months period ended 30 September 2024**

|   | <b>For the six-months period ended<br/>30 September</b> |                |
|---|---|----------------|
|   | <b>2024</b>   | <b>2023</b>    |
|   | <b>S\$'000</b>  | <b>S\$'000</b> |
| <b>Net increase/(decrease) in cash and cash equivalents</b> | 1,788   | (615)          |
| Cash and cash equivalents at 1 April                        | 16,146  | 24,557         |
| Effect of exchange rate fluctuations on cash held           | (139)   | 62             |
| <b>Cash and cash equivalents at 30 September</b>            | <u>17,795</u>   | <u>24,004</u>  |

For the purpose of the consolidated cash flow statement, cash and cash equivalents comprise the following at the end of the reporting period:

|  | <b>For the six-months period ended<br/>30 September</b> |                |
|--|---|----------------|
|  | <b>2024</b>   | <b>2023</b>    |
|  | <b>S\$'000</b>  | <b>S\$'000</b> |
| Cash at bank and fixed deposits  | 17,831  | 22,727         |
| Less: Fixed deposits with maturity more than 90 days at period end           | (36)  | (35)           |
| Less: Restricted fixed deposit   | –   | (28)           |
| Add: Cash at bank attributable to disposal group classified as held for sale | –   | 1,340          |
| Cash and cash equivalents in consolidated statement of cash flows            | <u>17,795</u>   | <u>24,004</u>  |

## **Econ Healthcare (Asia) Limited and its subsidiaries**

### **Notes to the condensed consolidated financial statements For the six-months period ended 30 September 2024**

---

#### **1 Corporate information**

Econ Healthcare (Asia) Limited (the “Company”) is a limited liability company incorporated and domiciled in Singapore and is listed on the Catalist Board of Singapore Exchange Securities Trading Limited (“SGX-ST”).

The registered office and principal place of business of the Company is located at 160 Changi Road, #05-01-13 Hexacube, Singapore 419728.

The immediate and ultimate holding companies are Econ Healthcare Pte. Ltd. and Econ Investment Holdings Pte. Ltd. respectively, both of which are incorporated in Singapore.

The principal activity of the Company is investment holding. The principal activities of the subsidiaries are those relating to the operation of medicare centres and nursing homes, provision of hospital extension ward management services, homecare services and ambulance services, emergency ambulance services and medical transport services, letting of properties and investment holding.

#### **2 Basis of preparation**

The condensed consolidated interim financial statements for the six months ended 30 September 2024 have been prepared in accordance with Singapore Financial Reporting Standards (International) (“SFRS(I)”) 1-34 *Interim Financial Reporting* by the Accounting Standards Council Singapore. The condensed consolidated financial statements do not include all of the information required for a complete set of financial statements. However, selected explanatory notes are included to explain the events and transactions that are significant to understanding of the changes in the Group’s financial position and performance since the last annual financial statements for the year ended 31 March 2024.

The condensed consolidated financial statements are presented in Singapore dollar (“S\$”) and all values are rounded to the nearest thousand (“S\$’000”), except when otherwise indicated.

##### **2.1 New and amended standards adopted by the Group**

The accounting policies adopted are consistent with those of the previous financial year which were prepared in accordance with SFRS(I)s, except in the current financial year, the Company has adopted all the new and revised standards which are effective for annual financial periods beginning on or after 1 April 2024. The adoption of these standards did not have any material effect on the financial performance or position of the Group.

## **Econ Healthcare (Asia) Limited and its subsidiaries**

### **Notes to the condensed consolidated financial statements For the six-months period ended 30 September 2024**

---

#### **2.2 Use of judgements and estimates**

In preparing the condensed consolidated financial statements, management has made judgements, estimates and assumptions that affect the application of the Group's accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates.

The significant judgements made by management in applying the Group's accounting policies and the key sources of estimation uncertainty were the same as those that applied to the consolidated financial statements as at and for the year ended 31 March 2024.

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimates are revised and in any future periods affected.

#### **3 Seasonal operations**

The Group's businesses are not affected significantly by seasonal or cyclical factors during the period under review.

#### **4 Segment information**

The Group has two (2) reportable segments, as described below, which are the Group's strategic business units. The strategic businesses are managed separately because they require different operation needs and marketing strategies. For each operating segment, the Group's Chief Executive Officer reviews the internal management reports on a monthly basis.

For the purpose of financial reporting, the following summary describes the operations in each of the Group's reportable segments:

- Medicare centres and nursing homes : Include provision of residential nursing care services, home care services, physiotherapy and rehabilitation services, clinical services and TCM treatments in medicare centres and nursing homes.
- Other operation and ancillary services : Include provision of management services, ambulance services, emergency ambulance services and medical transport services, course fees, the offering of TCM services at the Group's TCM clinics and other ancillary services.

**Econ Healthcare (Asia) Limited and its subsidiaries**

**Notes to the condensed consolidated financial statements  
For the six-months period ended 30 September 2024**

*Information about reportable segments*

|  | <b>Medicare<br/>centres and<br/>nursing<br/>homes<br/>S\$'000</b> | <b>Medicare<br/>centres and<br/>nursing<br/>homes<br/>(Discontinued<br/>operations)<br/>S\$'000</b> | <b>Other<br/>operation and<br/>ancillary<br/>services<br/>S\$'000</b> | <b>Eliminations<br/>and<br/>adjustments<br/>S\$'000</b> | <b>Total<br/>S\$'000</b> |
|--|---|---|---|---|--------------------------|
| <b>For the six-months period<br/>ended 30 September 2024</b>                     |   |   |   |   |                          |
| <b>Revenue</b>   |   |   |   |   |                          |
| External revenue   | 28,480  | 188   | 4,263   | (188)   | 32,743                   |
| Inter-segment revenue  | 4,493   | –   | –   | (4,493)   | –                        |
|  | <u>32,973</u>   | <u>188</u>  | <u>4,263</u>  | <u>(4,681)</u>  | <u>32,743</u>            |
| <b>Results:</b>  |   |   |   |   |                          |
| Segment results  | 4,901   | (50)  | (167)   | 738   | 5,422                    |
| Net finance costs  | 1,189   | (76)  | (30)  | (1,850)   | (767)                    |
| Share of losses of associates  | –   | –   | –   | –   | (139)                    |
| Unallocated expenses: Fair<br>value losses on investment in<br>quoted securities | –   | –   | –   | –   | (28)                     |
| Unallocated expenses: Gains on<br>disposal of investment in<br>quoted securities | –   | –   | –   | –   | 6                        |
| Segment profit before tax  | <u>6,090</u>  | <u>(126)</u>  | <u>(197)</u>  | <u>(1,112)</u>  | <u>4,494</u>             |
| <b>Significant non-cash items</b>  |   |   |   |   |                          |
| Depreciation of property, plant<br>and equipment                                 | 569   | –   | 434   | –   | 1,003                    |
| Depreciation of right-of-use<br>assets   | 3,348   | –   | 439   | –   | 3,787                    |
| Impairment losses on trade<br>receivables  | 24  | –   | –   | –   | 24                       |

**Econ Healthcare (Asia) Limited and its subsidiaries**

**Notes to the condensed consolidated financial statements  
For the six-months period ended 30 September 2024**

|  | <b>Medicare<br/>centres and<br/>nursing<br/>homes<br/>S\$'000</b> | <b>Medicare<br/>centres and<br/>nursing<br/>homes<br/>(Discontinued<br/>operations)<br/>S\$'000</b> | <b>Other<br/>operation and<br/>ancillary<br/>services<br/>S\$'000</b> | <b>Eliminations<br/>and<br/>adjustments<br/>S\$'000</b> | <b>Total<br/>S\$'000</b> |
|--|---|---|---|---|--------------------------|
| <b>For the six-months period<br/>ended 30 September 2023</b>                     |   |   |   |   |                          |
| <b>Revenue</b>   |   |   |   |   |                          |
| External revenue   | 24,054  | 324   | 445   | (324)   | 24,499                   |
| Inter-segment revenue  | –   | –   | 5,011   | (5,011)   | –                        |
|  | <u>24,054</u>   | <u>324</u>  | <u>5,456</u>  | <u>(5,335)</u>  | <u>24,499</u>            |
| <b>Results:</b>  |   |   |   |   |                          |
| Segment results  | 2,457   | (132)   | 320   | (51)  | 2,594                    |
| Net finance costs  | (1,197)   | (136)   | 94  | 823   | (416)                    |
| Unallocated expenses: Fair<br>value gains on investment in<br>quoted securities  | –   | –   | –   | –   | (23)                     |
| Unallocated expenses: Gains on<br>disposal of investment in<br>quoted securities | –   | –   | –   | –   | 27                       |
| Segment profit before tax  | <u>1,260</u>  | <u>(268)</u>  | <u>414</u>  | <u>772</u>  | <u>2,182</u>             |
| <b>Significant non-cash items</b>  |   |   |   |   |                          |
| Depreciation of property, plant<br>and equipment                                 | 547   | 169   | 92  | (169)   | 639                      |
| Depreciation of right-of-use<br>assets   | 2,827   | 167   | 896   | (167)   | 3,723                    |
| (Reversal of) impairment losses<br>on trade receivables                          | (4)   | –   | –   | –   | (4)                      |



**Econ Healthcare (Asia) Limited and its subsidiaries**

**Notes to the condensed consolidated financial statements  
For the six-months period ended 30 September 2024**

|   | Medicare<br>centres and<br>nursing<br>homes<br>S\$'000 | Medicare<br>centres and<br>nursing<br>homes<br>(Discontinued<br>operations)<br>S\$'000 | Other<br>operation and<br>ancillary<br>services<br>S\$'000 | Eliminations<br>S\$'000 | Total<br>S\$'000 |
|---|--|--|--|-------------------------|------------------|
| <b>As at 30 September 2024</b>  |  |  |  |                         |                  |
| <b>Assets:</b>  |  |  |  |                         |                  |
| Segment assets  | 78,074   | –  | 75,269   | (57,108)                | 96,235           |
| Tax assets  | 268  | –  | 187  | –                       | 455              |
| Total assets  | <u>78,342</u>  | <u>–</u>   | <u>75,456</u>  | <u>(57,108)</u>         | <u>96,690</u>    |
| <b>Liabilities:</b>   |  |  |  |                         |                  |
| Segment liabilities   | 70,369   | –  | 34,919   | (57,526)                | 47,762           |
| Tax liabilities   | 1,054  | –  | 183  | –                       | 1,237            |
| Total liabilities   | <u>71,423</u>  | <u>–</u>   | <u>35,102</u>  | <u>(57,526)</u>         | <u>48,999</u>    |
| Capital expenditure   | 274  | –  | 757  | –                       | 1,031            |
| <b>Total capital expenditure</b>  | <u>274</u>   | <u>–</u>   | <u>757</u>   | <u>–</u>                | <u>1,031</u>     |
| <b>As at 31 March 2024</b>  |  |  |  |                         |                  |
| <b>Assets:</b>  |  |  |  |                         |                  |
| Segment assets  | 76,850   | –  | 76,785   | (59,787)                | 93,848           |
| Tax assets  | 195  | –  | 231  | –                       | 426              |
| Assets of disposal group<br>classified as held for sale   | –  | 11,100   | –  | –                       | 11,100           |
| Total assets  | <u>77,045</u>  | <u>11,100</u>  | <u>77,016</u>  | <u>(59,787)</u>         | <u>105,374</u>   |
| <b>Liabilities:</b>   |  |  |  |                         |                  |
| Segment liabilities   | 74,373   | –  | 34,497   | (58,103)                | 50,767           |
| Tax liabilities   | 826  | –  | 298  | –                       | 1,124            |
| Liabilities directly associated<br>with disposal group<br>classified as held for sale             | –  | 8,995  | –  | –                       | 8,995            |
| Total liabilities   | <u>75,199</u>  | <u>8,995</u>   | <u>34,795</u>  | <u>(58,103)</u>         | <u>60,886</u>    |
| Capital expenditure   | 701  | –  | 806  | –                       | 1,507            |
| Capital expenditure to non-<br>current assets of disposal<br>group classified as held for<br>sale | –  | 300  | –  | –                       | 300              |
| <b>Total capital expenditure</b>  | <u>701</u>   | <u>300</u>   | <u>806</u>   | <u>–</u>                | <u>1,807</u>     |

## Econ Healthcare (Asia) Limited and its subsidiaries

### Notes to the condensed consolidated financial statements For the six-months period ended 30 September 2024

---

#### *Geographical information*

External customers of the Group are located in Singapore, Malaysia and China. The Group carries out its operations in Singapore, Malaysia and China and all the Group's non-current assets are located in Singapore, Malaysia and China.

In presenting the information on the basis of geographical segments, segmental revenue is based on the geographical location of the customers and segmental assets are based on the geographical location of the assets.

|                         | For the six-months period<br>ended 30 September |                 |
|-------------------------|---|-----------------|
|                         | 2024<br>S\$'000                                 | 2023<br>S\$'000 |
| <b>Revenue</b>          |   |                 |
| Singapore               | 29,537  | 21,636          |
| Malaysia                | 3,206   | 2,863           |
| China                   | 188   | 324             |
| Discontinued operations | (188)   | (324)           |
| Consolidated revenue    | <u>32,743</u>                                   | <u>24,499</u>   |

|   | 30 September    | 31 March        |
|---|-----------------|-----------------|
|   | 2024<br>S\$'000 | 2023<br>S\$'000 |
| <b>Non-current assets<sup>(1)</sup></b> |                 |                 |
| Singapore                               | 44,473          | 46,881          |
| Malaysia                                | 20,911          | 19,356          |
| Consolidated total non-current assets   | <u>65,384</u>   | <u>66,237</u>   |

<sup>(1)</sup> Non-current assets information presented above consist of property, plant and equipment, right-of-use assets, investment property, non-current trade and other receivables, investment in associates and intangible asset.

**Econ Healthcare (Asia) Limited and its subsidiaries**

**Notes to the condensed consolidated financial statements  
For the six-months period ended 30 September 2024**

**5**

**Revenue**

| For the six-months period ended 30 September | Medicare centres and nursing homes fees |   |                                       |                           | Ancillary fees         |                           |  |                                     | Total<br>S\$'000 |
|--|---|---|---------------------------------------|---------------------------|------------------------|---------------------------|--|-------------------------------------|------------------|
|  | Home fees<br>S\$'000                    | Home care and day care and other nursing home services<br>S\$'000 | Operating subvention grant<br>S\$'000 | Ambulance fees<br>S\$'000 | Course fees<br>S\$'000 | Management fee<br>S\$'000 | Traditional Chinese medicine ("TCM") clinics services<br>S\$'000 | Other ancillary services<br>S\$'000 |                  |
|  |   |   |                                       |                           |                        |                           |  |                                     |                  |
| <b>2024</b>                                  |   |   |                                       |                           |                        |                           |  |                                     |                  |
| Third parties                                |   |   |                                       |                           |                        |                           |  |                                     |                  |
| - Singapore                                  | 7,752                                   | 2,034   | 15,488                                | 3,905                     | 4                      | –                         | 342  | –*                                  | 29,525           |
| - Malaysia                                   | 2,213                                   | 993   | –                                     | –                         | –                      | –                         | –  | –                                   | 3,206            |
|  | 9,965                                   | 3,027   | 15,488                                | 3,905                     | 4                      | –                         | 342  | –*                                  | 32,731           |
| Related corporation                          |   |   |                                       |                           |                        |                           |  |                                     |                  |
| - Singapore                                  | –                                       | –   | –                                     | –                         | –                      | 12                        | –  | –                                   | 12               |
|  | 9,965                                   | 3,027   | 15,488                                | 3,905                     | 4                      | 12                        | 342  | –*                                  | 32,743           |
| <b>2023</b>                                  |   |   |                                       |                           |                        |                           |  |                                     |                  |
| Third parties                                |   |   |                                       |                           |                        |                           |  |                                     |                  |
| - Singapore                                  | 6,622                                   | 2,066   | 12,503                                | –                         | –*                     | –                         | 432  | –*                                  | 21,624           |
| - Malaysia                                   | 1,982                                   | 881   | –                                     | –                         | –                      | –                         | –  | –                                   | 2,863            |
|  | 8,604                                   | 2,947   | 12,503                                | –                         | –*                     | –                         | 432  | –*                                  | 24,487           |
| Related corporation                          |   |   |                                       |                           |                        |                           |  |                                     |                  |
| - Singapore                                  | –                                       | –   | –                                     | –                         | –                      | 12                        | –  | –                                   | 12               |
|  | 8,604                                   | 2,947   | 12,503                                | –                         | –*                     | 12                        | 432  | –*                                  | 24,499           |

\* Less than S\$1,000

Home fees generally relate to the Medicare Centres and Nursing Homes' contracts with patients in which performance obligations are to provide nursing home healthcare services to individual patients in Singapore, Malaysia and China. Homecare and day care fees generally relates to contracts with patients in which performance obligations are to provide healthcare services to individual patients at their homes and day care centres. Other nursing home services relate to provision of dressing, rehabilitation services, Traditional Chinese Medicine ("TCM") treatments and other medical related services to individual patients.

Ambulance fees relate to provision of medical and passenger transport services to hospitals and individual patients in Singapore. Course fees relate to contracts with corporate customers in which performance obligations are to provide training for nurses, nursing home managers and home caregivers in Singapore. Management fee relates to provision of management and consultancy services to related corporations. Related corporations are other related parties not within the Group that are owned by the majority shareholder. TCM clinic services relate to the offering of TCM services at TCM clinics.

## Econ Healthcare (Asia) Limited and its subsidiaries

### Notes to the condensed consolidated financial statements For the six-months period ended 30 September 2024

---

Invoices are issued based on contractual terms. The Group has a credit term of 10 to 30 days which is typically short term, in line with market practice, without any financing component. There are no variable considerations, and no obligations for returns or refunds or warranties for healthcare-related services.

Operating subvention grants are government subsidies given to patients and are paid by the Government on behalf of the patients to the Singapore nursing homes for the subsidised amounts and is a revenue to the Group. The subvention grant scheme requires the Group to set aside a portion of its beds for eligible patients who meet the means test criteria to enjoy the subsidies.

The performance obligations for nursing home healthcare services, home care services, management services and training services are generally satisfied over time and revenue is recorded when the services are performed. The performance obligations for ambulance services, TCM and other ancillary services are generally satisfied at a point in time.

#### 6 Other income

|   | For the six-months<br>period ended 30 September |              |
|---|---|--------------|
|   | 2024  | 2023         |
|   | S\$'000   | S\$'000      |
| Other government grants:  |   |              |
| - Grants on senior employment credit, enabling<br>employment credit, CPF transition offset and wages<br>credit scheme | 243   | 18           |
| - Eldercare centre baseline service transition grants   | –   | 60           |
| - Active Ageing Centre fundings   | 345   | 167          |
| - Grants on community care salary enhancements  | 337   | 67           |
| - Rental subvention grants  | 1,297   | 1,297        |
| - Pre-operations funding  | –   | 199          |
| Rental income   | 140   | 133          |
| Amortisation of deferred capital grants   | 191   | 141          |
| Dividend income from quoted securities  | 21  | 49           |
| Others  | 130   | 213          |
|   | <u>2,704</u>                                    | <u>2,344</u> |

**Econ Healthcare (Asia) Limited and its subsidiaries**

**Notes to the condensed consolidated financial statements  
For the six-months period ended 30 September 2024**

---

**7 Finance costs, net**

|  | <b>For the six-months<br/>period ended 30 September</b> |                |
|--|---|----------------|
|  | <b>2024</b>   | <b>2023</b>    |
|  | <b>S\$'000</b>  | <b>S\$'000</b> |
| Interest income from bank deposits                     | 57  | 201            |
| Exchange gain, net                                     | –   | 1              |
| Finance income   | <u>57</u>   | <u>202</u>     |
| Exchange loss, net                                     | (161)   | –              |
| Interest expense on bank borrowings                    | (78)  | (122)          |
| Unwinding of discount on provision of restoration cost | (8)   | (3)            |
| Interest expense from lease liabilities                | <u>(577)</u>  | <u>(493)</u>   |
| Finance costs  | <u>(824)</u>  | <u>(618)</u>   |
| Net finance costs                                      | <u>(767)</u>  | <u>(416)</u>   |

**8 Profit before tax from continuing operations**

The following items have been included in arriving at profit before tax from continuing operations:

|   | <b>For the six-months<br/>period ended 30 September</b> |                |
|---|---|----------------|
|   | <b>2024</b>   | <b>2023</b>    |
|   | <b>S\$'000</b>  | <b>S\$'000</b> |
| Write-off of property, plant and equipment                          | 12  | 2              |
| Expenses relating to short-term leases presented in “staff costs”   | 171   | 111            |
| Repair and maintenance expenses                                     | 798   | 713            |
| Contributions to defined contribution plans included in staff costs | 838   | 606            |
| Directors fees  | 86  | 86             |
| Gain on disposal of subsidiaries and associate                      | (809)   | –              |
| Impairment losses in investment in associates                       | <u>479</u>  | <u>–</u>       |

**Econ Healthcare (Asia) Limited and its subsidiaries**

**Notes to the condensed consolidated financial statements  
For the six-months period ended 30 September 2024**

---

**9 Income tax expense**

The Group calculates the period income tax expense using the tax rate that would be applicable to the expected total annual earnings. The major components of income tax expense for the six months ended 30 September 2024 and 2023 are:

|  | <b>For the six-months<br/>period ended 30 September</b> |                |
|--|---|----------------|
|  | <b>2024</b>   | <b>2023</b>    |
|  | <b>S\$'000</b>  | <b>S\$'000</b> |
| Current tax expense  | 785   | 440            |
| Deferred tax credit  | (1)   | (96)           |
| Income tax expense attributable to continuing operations   | 784   | 344            |
| Income tax expense attributable to discontinued operations | —   | —              |
| Income tax expense recognised in profit or loss            | <u>784</u>  | <u>344</u>     |

**10 Property, plant and equipment**

During the six-months period ended 30 September 2024, the Group had total additions to property, plant and equipment of S\$1,031,000 (six-months period ended 2023: S\$625,000).

**11 Right-of-use assets**

During the six-months period ended 30 September 2024, the Group recognised additions to right-of-use assets of S\$Nil (six-month period ended 30 September 2023: S\$213,000).

**Econ Healthcare (Asia) Limited and its subsidiaries**

**Notes to the condensed consolidated financial statements  
For the six-months period ended 30 September 2024**

---

**12 Investment property**

|  | <b>30 September<br/>2024<br/>S\$'000</b> | <b>31 March<br/>2024<br/>S\$'000</b> |
|--|--|--------------------------------------|
| At beginning of the period/year, at cost | 7,177                                    | 7,554                                |
| Translation differences on consolidation | 641                                      | (377)                                |
| At end of the period/year                | <u>7,818</u>                             | <u>7,177</u>                         |

Investment property comprises a freehold land that is leased to a third party during the period/year. The lease contains an initial non-cancellable period of three years with option to renew for additional three years.

**Amounts recognised in profit or loss**

|                           | <b>For the six-months<br/>period ended 30 September</b> |                         |
|---------------------------|---|-------------------------|
|                           | <b>2024<br/>S\$'000</b>                                 | <b>2023<br/>S\$'000</b> |
| Rental income             | 140   | 132                     |
| Direct operating expenses | <u>(6)</u>  | <u>(2)</u>              |

**Investment property is measured at cost but for which fair value is disclosed**

As at 30 September 2024, the fair value of the investment property amounted to S\$7,809,000 (31 March 2024: S\$7,168,000).

The fair value of investment property located in Malaysia is determined by an independent valuer who has appropriate recognised professional qualifications and recent experience in the location and category of properties being valued.

The investment property is categorised under Level 3 of the fair value measurement hierarchy. The fair value of investment property is based on market value using direct comparison method. It is an estimated amount for which a property could be exchanged on the date of the valuation between a willing buyer and a willing seller in an arm's length transaction after proper marketing wherein the parties had each acted knowledgeably. Due adjustments for difference between the properties and the comparables in terms of location, tenure, size, shape, floor level, age and conditions of properties and date of transactions affecting its value were made in arriving at the fair value of investment property.

**Econ Healthcare (Asia) Limited and its subsidiaries**

**Notes to the condensed consolidated financial statements  
For the six-months period ended 30 September 2024**

**13 Trade and other receivables**

|  | Group                           |                             | Company                         |                             |
|--|---------------------------------|-----------------------------|---------------------------------|-----------------------------|
|  | 30 September<br>2024<br>S\$'000 | 31 March<br>2024<br>S\$'000 | 30 September<br>2024<br>S\$'000 | 31 March<br>2024<br>S\$'000 |
| Trade receivables – third parties  | 3,634                           | 3,150                       | –                               | –                           |
| Less: Impairment losses  | (322)                           | (285)                       | –                               | –                           |
|  | 3,312                           | 2,865                       | –                               | –                           |
| Trade receivables – subsidiaries   | –                               | –                           | 4,395                           | 5,065                       |
| Impairment losses  | –                               | –                           | (1,055)                         | (1,055)                     |
|  | 3,312                           | 2,865                       | 3,340                           | 4,010                       |
| Receivables for operating subvention grants                                    | 6,539                           | 2,261                       | –                               | –                           |
| Aggregate of trade receivables and receivables for operating subvention grants | 9,851                           | 5,126                       | 3,340                           | 4,010                       |
| Other government grant receivables   | 1,328                           | 3,447                       | –                               | 77                          |
| Other receivables  | 729                             | 872                         | 9                               | 849                         |
| Staff advances   | 28                              | 14                          | 1                               | –                           |
| Deposits   | 2,573                           | 2,729                       | 391                             | 768                         |
| Non-trade amounts due from subsidiaries  | –                               | –                           | 3,286                           | 2,533                       |
| Impairment losses  | –                               | –                           | (678)                           | (678)                       |
| Financial assets at amortised cost   | 14,509                          | 12,188                      | 6,349                           | 7,559                       |
| Prepayments  | 554                             | 472                         | 186                             | 172                         |
|  | 15,063                          | 12,660                      | 6,535                           | 7,731                       |
| Non-current  | 2,617                           | 2,302                       | 3,099                           | 3,275                       |
| Current  | 12,446                          | 10,358                      | 3,436                           | 4,456                       |
|  | 15,063                          | 12,660                      | 6,535                           | 7,731                       |

Trade receivables are non-interest bearing and are generally on terms of 10-30 days.

Non-trade amounts due from subsidiaries are unsecured, interest-free and repayable on demand.

The Group's non-current amounts relate mainly to security deposits paid for leased premises. The security deposits are interest-free and are refundable at lease expiry or earlier termination of the lease.

The Company's non-current amounts relate mainly to trade amounts due from subsidiaries, which are unsecured, interest-free, repayable on demand and not expected to be repaid within 12 months.



**Econ Healthcare (Asia) Limited and its subsidiaries**

**Notes to the condensed consolidated financial statements  
For the six-months period ended 30 September 2024**

---

**14 Share capital**

|  | Number of shares     |                    | Amount                          |                             |
|--|----------------------|--------------------|---------------------------------|-----------------------------|
|  | 30 September<br>2024 | 31 March<br>2024   | 30 September<br>2024<br>S\$'000 | 31 March<br>2024<br>S\$'000 |
| <b>Group and Company</b>                             |                      |                    |                                 |                             |
| Issued and fully paid ordinary shares, at par value: |                      |                    |                                 |                             |
| In issue at beginning of the period/year             | 265,910,891          | 257,000,000        | 29,983                          | 28,255                      |
| Shares issued during the period/year                 | –                    | 8,910,891          | –                               | 1,728                       |
| In issue at end of the period/year                   | <u>265,910,891</u>   | <u>265,910,891</u> | <u>29,983</u>                   | <u>29,983</u>               |

***Ordinary shares***

The holders of ordinary shares are entitled to receive dividends as declared from time to time, and are entitled to one vote per share at meetings of the Company. All shares rank equally with regard to the Company's residual assets.

As at 30 September 2024 and 31 March 2024, there were no treasury shares held by the Company and there were no subsidiary holdings.

**15 Reserves**

***Currency translation reserve***

The currency translation reserve comprises all foreign exchange differences arising from the translation of the financial statements of foreign operations.

***Merger reserve***

Merger reserve represents reserve arising from the business combinations through common control.

***Dividends***

During the six months ended 30 September 2024, the Group declared and paid dividend in amount of S\$1,675,000 (S\$0.0063 per ordinary share) (six-month period ended 30 September 2023: S\$1,131,000 (S\$0.0044 per ordinary share)).

**Econ Healthcare (Asia) Limited and its subsidiaries**

**Notes to the condensed consolidated financial statements  
For the six-months period ended 30 September 2024**

**16 Net asset value per share**

|   | <b>Group</b>                 |                          | <b>Company</b>               |                          |
|---|------------------------------|--------------------------|------------------------------|--------------------------|
|   | <b>30 September<br/>2024</b> | <b>31 March<br/>2024</b> | <b>30 September<br/>2024</b> | <b>31 March<br/>2024</b> |
| Net asset value per ordinary share (in cents) | 18.13                        | 16.70                    | 16.26                        | 16.97                    |

**17 Earnings per share**

***Basic earnings per share***

The basic earnings per share is calculated by dividing the Group's profit for the period/year, attributable to owner of the Company by the weighted-average number of ordinary shares outstanding and on a fully diluted basis during the year.

The following tables reflect the profit and share data used in the computation of basic earnings per share for the period ended 30 September:

|  | <b>For the six-months<br/>period ended 30 September</b> |                         |
|--|---|-------------------------|
|  | <b>2024<br/>S\$'000</b>                                 | <b>2023<br/>S\$'000</b> |
| Profit from continuing operations, net of tax              | 3,665   | 1,867                   |
| Loss from discontinued operations, net of tax              | (91)  | (188)                   |
| Profit for the period attributable to owner of the Company | <u>3,574</u>  | <u>1,679</u>            |

|  | <b>For the six-months<br/>period ended 30 September</b> |                               |
|--|---|-------------------------------|
|  | <b>2024<br/>No. of shares</b>                           | <b>2023<br/>No. of shares</b> |
| Weighted-average number of ordinary shares | <u>265,910,891</u>                                      | <u>257,000,000</u>            |

**Econ Healthcare (Asia) Limited and its subsidiaries**

**Notes to the condensed consolidated financial statements  
For the six-months period ended 30 September 2024**

|  | <b>For the six-months<br/>period ended 30 September</b> |                      |
|--|---|----------------------|
|  | <b>2024</b>   | <b>2023</b>          |
|  | <b>No. of shares</b>                                    | <b>No. of shares</b> |
| <b>Earnings per share for the period from continuing operations attributable to owner of the Company</b> |   |                      |
| Basic and diluted earnings per share (cents)   | 1.38  | 0.73                 |
| <b>Earnings per share for the period</b>   |   |                      |
| Basic and diluted earnings per share (cents)   | 1.34  | 0.65                 |

***Diluted earnings per share***

As at 30 September 2024 and 30 September 2023, there were no outstanding dilutive potential ordinary shares.

**18 Loans and borrowings**

|                                   | <b>30 September<br/>2024</b> | <b>31 March<br/>2024</b> |
|-----------------------------------|------------------------------|--------------------------|
|                                   | <b>S\$'000</b>               | <b>S\$'000</b>           |
| <b>Non-current liabilities</b>    |                              |                          |
| Secured bank loans                | 1,013                        | 1,242                    |
|                                   | 1,013                        | 1,242                    |
| <b>Current liabilities</b>        |                              |                          |
| Unsecured bank loans              | 809                          | 1,913                    |
| Secured bank loans                | 599                          | 469                      |
|                                   | 1,408                        | 2,382                    |
| <b>Total loans and borrowings</b> | 2,421                        | 3,624                    |

***Terms and debt repayment schedule***

The terms and conditions of outstanding loans and borrowings are as follows:

|                                | <b>Note</b> | <b>Currency</b> | <b>Nominal<br/>interest rate<br/>%</b> | <b>Year of<br/>maturity</b> | <b>Face<br/>value<br/>S\$'000</b> | <b>Carrying<br/>amount<br/>S\$'000</b> |
|--------------------------------|-------------|-----------------|--|-----------------------------|-----------------------------------|--|
| <b>30 September 2024 Group</b> |             |                 |  |                             |                                   |  |
| Secured bank loans             | A           | MYR             | Base lending rate –<br>1.25%           | 2027                        | 1,612                             | 1,612                                  |
| Unsecured revolving credit     | B           | MYR             | Cost of funds + 1.50%                  | 2024                        | 809                               | 809                                    |
|                                |             |                 |  |                             | 2,421                             | 2,421                                  |

**Econ Healthcare (Asia) Limited and its subsidiaries**

**Notes to the condensed consolidated financial statements  
For the six-months period ended 30 September 2024**

|                            | Note | Currency | Nominal interest rate     | Year of maturity | Face value   | Carrying amount |
|----------------------------|------|----------|---------------------------|------------------|--------------|-----------------|
| <b>31 March 2024 Group</b> |      |          |                           |                  |              |                 |
| Secured bank loans         | A    | MYR      | Base lending rate – 1.25% | 2027             | 1,711        | 1,711           |
| Unsecured revolving credit | B    | MYR      | Cost of funds + 1.50%     | 2024             | 1,913        | 1,913           |
|                            |      |          |                           |                  | <u>3,624</u> | <u>3,624</u>    |

- A) The bank loan was secured by the Group's freehold land and building amounting to S\$8,465,466 (31 March 2024: S\$7,856,000).
- B) As at 30 September 2024 and 31 March 2024, the bank loan is unsecured and a subsidiary of the Group shall maintain a tangible net worth of not less than RM40,000,000 and gearing ratio shall not exceed 0.75 times.

**19 Trade and other payables**

|   | Group                        |                          | Company                      |                          |
|---|------------------------------|--------------------------|------------------------------|--------------------------|
|   | 30 September 2024<br>S\$'000 | 31 March 2024<br>S\$'000 | 30 September 2024<br>S\$'000 | 31 March 2024<br>S\$'000 |
| Trade payables – third parties                            | 1,099                        | 1,257                    | –                            | –                        |
| Non-trade amount due to subsidiaries                      | –                            | –                        | 201                          | 181                      |
| Accrued operating expenses                                | 5,051                        | 2,825                    | 1,475                        | 1,314                    |
| Interest payables   | –                            | –                        | –                            | –                        |
| Other payables  | 518                          | 683                      | 50                           | 49                       |
| Payables to suppliers of property, plant and equipment    | 338                          | 331                      | 330                          | 330                      |
| Refundable deposits                                       | 1,518                        | 1,530                    | –                            | –                        |
| Financial liabilities at amortised cost                   | 8,524                        | 6,626                    | 2,056                        | 1,874                    |
| Deferred grant income                                     | 247                          | 122                      | –                            | –                        |
| Liability for short-term accumulated compensated absences | 308                          | 308                      | 146                          | 146                      |
| Home fees collected in advance                            | 88                           | 99                       | –                            | –                        |
|   | <u>9,167</u>                 | <u>7,155</u>             | <u>2,202</u>                 | <u>2,020</u>             |

Trade payables are non-interest bearing and are generally on terms of 30 days.

Non-trade amounts due to subsidiaries are unsecured, interest-free and repayable on demand.

**Econ Healthcare (Asia) Limited and its subsidiaries**

**Notes to the condensed consolidated financial statements  
For the six-months period ended 30 September 2024**

---

**20 Related parties**

***Key management personnel compensation***

Key management personnel of the Group are those persons having the authority and responsibility for planning, directing and controlling the activities of the Group. The Board of Directors and senior management team are considered as key management personnel.

|  | <b>For the six-months<br/>period ended 30 September</b> |                |
|--|---|----------------|
|  | <b>2024</b>   | <b>2023</b>    |
|  | <b>S\$'000</b>  | <b>S\$'000</b> |
| Post-employment benefits                             | 25  | 28             |
| Short term employee benefits including director fees | 755   | 734            |
| Non-monetary benefit                                 | 93  | 76             |
|  | <u>873</u>  | <u>838</u>     |

***Other related party transactions***

Other than disclosed elsewhere in the financial statements, transactions with related parties are as follows:

|                              | <b>For the six-months<br/>period ended 30 September</b> |                |
|------------------------------|---|----------------|
|                              | <b>2024</b>   | <b>2023</b>    |
|                              | <b>S\$'000</b>  | <b>S\$'000</b> |
| <b>Related corporations*</b> |   |                |
| Management fee income        | (9)   | (9)            |
| Rental income                | <u>(2)</u>  | <u>(2)</u>     |

\*Related corporations are other related parties not within the Group that are owned by the majority shareholder.

## **Econ Healthcare (Asia) Limited and its subsidiaries**

### **Notes to the condensed consolidated financial statements For the six-months period ended 30 September 2024**

---

#### **21 Discontinued operations and disposal group held for sale**

During the financial year ended 31 March 2024, the Group undertook a strategic review of its China operations and had committed in a sale plan to partially dispose 11% and 21% of its interest in China subsidiaries, Chongqing Yikang Bailingbang Eldercare Co., Ltd., Chongqing Changshou Yikang Bailingbangyanjia Eldercare Co., Ltd. (“China subsidiaries”) and full interest in the associate, Sichuan Guangda Bailingbang Yikang Eldercare Co., Ltd. (collectively known as “China Group”). The aggregate consideration for the divestments is approximately S\$701,000 (Renminbi \$3.5 million) and shall be paid by way of cash over three consecutive years and was arrived at on a willing-buyer, willing-seller basis.

As at 31 March 2024, the assets and liabilities related to the China subsidiaries had been presented in the consolidated balance sheet as “assets of disposal group classified as held for sale” and “liabilities directly associated with disposal group classified as held for sale”, and its results are presented separately on the consolidated income statement and statement of comprehensive income as “Loss from discontinued operations, net of tax”.

On 27 June 2024, the disposal was completed and the Group recognised gain on disposal of subsidiaries and associate of S\$809,000. Following the disposal, Chongqing Yikang Bailingbang Eldercare Co., Ltd. and Chongqing Changshou Yikang Bailingbangyanjia Eldercare Co., Ltd.. ceased as subsidiaries of the Group and retained a non-controlling interest of 49% in both entities

#### **22 Intangible asset**

##### Acquisition of Ambulance Medical Service Pte. Ltd.

On 5 March 2024, the Group completed its acquisition of 100% of the equity interest in Ambulance Medical Service Pte. Ltd. (“AMS”). AMS was established in 2007 and is in the business of providing of emergency ambulance and medical evacuation services, as well as event medical standby services. As disclosed in the circular to shareholders dated 6 December 2023, the acquisition of AMS and the diversification of the Group’s core business to include the provision of emergency ambulance services and medical transport services will allow the Group to diversify its business in order to enhance its service offerings that are complementary to the Group’s existing core business and integrate with its existing network of medical centres and nursing homes.

##### Provisional goodwill arising from acquisition

The goodwill of S\$5,129,000 represents synergies expected to be achieved from the comprehensive integration of the emergency ambulance services business into the existing healthcare ecosystem established within the Group. The goodwill is provisional and pending finalisation of the purchase price allocation exercise to be completed in FY2025.

## Econ Healthcare (Asia) Limited and its subsidiaries

### Other information required for Half Year Announcement

---

**1 Whether the figures have been audited or reviewed, and in accordance with which auditing standard or practice.**

The condensed interim consolidated statement of financial position of the Group as at 30 September 2024 and the related interim consolidated profit or loss and other comprehensive income, interim consolidated statement of changes in equity and interim consolidated statement of cash flows for the six months period ended 30 September 2024 and selected explanatory notes have not been audited or reviewed by our auditors.

**2 Where the figures have been audited or reviewed, the auditors' report (including any qualifications or emphasis of matter)**

Not applicable as the figures have not been audited or reviewed by the auditors.

**3 Where the latest financial statements are subject to an adverse opinion, qualified opinion or disclaimer of opinion:-**

**(a) Updates on the efforts taken to resolve each outstanding audit issue.**

**(b) Confirmation from the Board that the impact of all outstanding audit issues on the financial statements have been adequately disclosed.**

**This is not required for any audit issue that is a material uncertainty relating to going concern.**

Not applicable, there is no adverse opinion, qualified opinion or disclaimer of opinion in relation to the latest financial statements.

**4 A review of the performance of the group, to the extent necessary for a reasonable understanding of the group's business. The review must discuss any significant factors that affected the turnover, costs, and earnings of the group for the current financial period reported on, including (where applicable) seasonal or cyclical factors. It must also discuss any material factors that affected the cash flow, working capital, assets or liabilities of the group during the current financial period reported on**

**(A) Statement of comprehensive income**

***6M2025 vs 6M2024***

***Revenue***

Revenue increased by 33.7% or S\$8.2 million, from S\$24.5 million in 6M2024 to S\$32.7 million in 6M2025 mainly due to an increase in S\$4.4 million in Medicare centres and nursing home fees and S\$3.8 million in ancillary fees.

The increase in Medicare centres and nursing home fees was attributable to (i) increase of \$4.1 million from Singapore mainly attributable to nursing homes fees revision and fully ramped up operations of the ECON Care Residences (Henderson), (ii) increase of S\$0.3 million from Malaysia a result of a net increase in the bed occupancy of 24 for both ECON Medicare Centre and Nursing Home – Puchong and ECON Medicare Centre and Nursing Home –Taman Perling.

## **Econ Healthcare (Asia) Limited and its subsidiaries**

### **Other information required for Half Year Announcement**

---

Ancillary fees increased by S\$3.8 million from S\$0.4 million in 6M2024 to S\$4.2 million in 6M2025 mainly due to an increase in ambulance fees, attributable to the completion of the Group's acquisition of AMS on 5 March 2024.

As at 30 September 2024, our monthly average bed capacity from continuing operations stood at 1,419. The Group had achieved an overall bed occupancy of 92.4% in 6M2025, compared to 88.4% in 6M2024, which was mainly due to an increase in the occupancy rates for ECON Care Residences (Henderson), Medicare Centre and Nursing Home – Puchong and ECON Medicare Centre and Nursing Home –Taman Perling.

#### ***Other income***

Other income increased by 15.4%, or S\$0.4 million from S\$2.3 million in 6M2024 to S\$2.7 million in 6M2025. The increase was mainly attributed to higher government grants of S\$0.2 million from progressive wage scheme and senior employment credit and increase in community care salary enhancements of S\$0.3 million. These increases were offset by decrease in pre-operations funding of S\$0.2 million for the purpose of facilitating the ramping up of operations for ECON Care Residences (Henderson).

#### ***Supplies and consumables***

Supplies and consumables increased by 2.8%, or S\$0.1 million, from S\$3.3 million in 6M2024 to S\$3.4 million in 6M2025 mainly due to purchases of supplies and consumables for AMS.

#### ***Staff costs***

Staff costs increased by 35.5%, or S\$4.8 million from S\$13.6 million in 6M2024 to S\$18.4 million in 6M2025. The increase is mainly due to S\$2.8 million of staff costs incurred for the consolidation of AMS and S\$2.0 million of staff costs incurred for increase in headcount and salary increments and bonuses in the remaining nursing homes and support function.

#### ***Depreciation of property, plant and equipment***

Depreciation of property, plant and equipment increased by 57.0%, or S\$0.4 million from S\$0.6 million in 6M2024 to S\$1.0 million in 6M2025. The increase is mainly due to depreciation charges from the acquisition of property, plant and equipment of AMS.

#### ***Depreciation of right-of-use assets***

Depreciation of right-of-use assets increased by 1.7% or S\$0.1 million from S\$3.7 million to S\$3.8 million. The increase is mainly due to depreciation charges of right-of-use asset of AMS.

#### ***Utilities expenses***

Utilities expense remained fairly comparable at S\$0.8 million for both 6M2024 and 6M2025.



## Econ Healthcare (Asia) Limited and its subsidiaries

### Other information required for Half Year Announcement

---

#### *Other operating expenses*

Other operating expenses increased by 19.2%, or S\$0.4 million, from S\$2.2 million in 6M2024 to S\$2.6 million in 6M2025. The increase was mainly due to consolidation of AMS other operating expenses of S\$0.6 million and impairment losses on investment in associates of S\$0.5 million. The increase was offset by the gain on disposal of subsidiaries and associate of S\$0.8 million.

#### *Finance costs, net*

Net finance costs increased by 84.4%, or S\$0.4 million, from S\$0.4 million in 6M2024 to S\$0.8 million in 6M2025 mainly due to decrease in interest income of S\$0.2 million from fixed deposits and exchange loss of S\$0.2 million as a result of Malaysia Ringgit appreciate against Singapore dollar.

#### *Profit before tax from continuing operations*

Profit before tax from continuing operations increased by 106.0%, or S\$2.3 million, from S\$2.2 million in 6M2024 to S\$4.5 million in 6M2025.

#### *Tax expense*

Tax expense increased by 127.9%, or S\$0.4 million, from S\$0.3 million in 6M2024 to S\$0.8 million in 6M2025 due to higher profit before tax.

#### *Discontinued operations*

Discontinued operations relate to the China subsidiaries and associate as the Group had classified the China subsidiaries and associate as “Discontinued operations” in consolidated income statement and disposal group held for sale in consolidated balance sheet (Note 21).

#### *Profit from continuing operations attributable to owner of the Company (PATMI from continuing operations)*

As a result of the foregoing, the Group’s PATMI from continuing operations increased by S\$1.8 million, from S\$1.9 million in 6M2024 to S\$3.7 million in 6M2025. PATMI from continuing operations margin increased from 7.6% in 6M2024 to 11.2% in 6M2025.

*Earnings per share (EPS) for the year from continuing operations* on a fully diluted basis for 6M2025 was 1.38 cents compared to 0.73 cents for 6M2024.

*Net asset value (NAV)* per share was 18.13 cents as at 30 September 2024 compared to 16.70 cents as at 31 March 2024.

### **(B) Statement of financial position**

#### *Non-current assets*

As at 30 September 2024, non-current assets of S\$65.7 million accounted for 68.0% of the Group’s total assets. Non-current assets comprised the following:

- (i) property, plant and equipment, which amounted to S\$17.5 million, and comprised freehold land and buildings, properties under construction, leasehold improvements and renovations, nursing homes equipment, ambulances and medical equipment, furniture, fittings and office equipment, computers and accessories and motor vehicles;

## **Econ Healthcare (Asia) Limited and its subsidiaries**

### **Other information required for Half Year Announcement**

- (ii) right-of-use assets, which amounted to S\$31.3 million, and comprised nursing homes, office premise and health and wellness centres, office equipment, staff accommodation and motor vehicles;
- (iii) investment property, which amounted to S\$7.8 million, and is related to a freehold land owned by the Group in Cheras, Malaysia. The land was leased to a third-party lessee to operate an education centre;
- (iv) trade and other receivables, which amounted to S\$2.6 million, and is mainly related to security deposits paid to our landlords and utilities providers;
- (v) deferred tax assets, which amounted to S\$0.3 million, in relation to lease accounting, provisions and tax loss carry-forwards; and
- (vi) intangible asset of S\$5.1 million, arising from the recognition of the provisional goodwill from the consolidation of AMS, pending the purchase price exercise to be finalised by end of FY2025.
- (vii) investment in associates, amounting to S\$1.1 million, of which the Group's interest is 49% for the two associates.

Non-current assets decreased by S\$0.9 million from S\$66.6 million as at 31 March 2024 to S\$65.7 million as at 30 September 2024. This was mainly due to decrease in right-of-use assets of S\$3.8 million resulting from depreciation charges incurred during the period. The decrease is offset by increase in property, plant and equipment of \$0.9 million, increase in investment in associates of S\$1.1 million and increase in investment property of S\$0.6 million due to translation differences as Malaysian Ringgit appreciate against the Singapore dollar.

#### ***Current assets***

As at 30 September 2024, current assets of S\$30.9 million accounted for 32.0% of total assets. Current assets mainly comprised the following:

- (i) trade and other receivables, which amounted to S\$12.4 million, comprising S\$3.3 million of net third party trade receivables, S\$6.5 million of receivables for operating subvention grants, S\$1.3 million of other government grant receivables, S\$0.6 million prepayments, and cumulatively accounted for 94.4% of total trade and other receivables;
- (ii) investment in quoted securities, which amounted to S\$0.6 million;
- (iii) cash and short-term deposits, which amounted to S\$17.8 million;
- (iv) current tax assets, which amounted to S\$0.1 million; and

Current assets decreased by S\$7.8 million from S\$38.8 million as at 31 March 2024 to S\$30.9 million as at 30 September 2024. The decrease is mainly due to completion of the disposal of the discontinued operations assets resulting in decrease in assets of disposal group classified as held for sale of S\$11.1 million and decrease in investments in quoted shares of S\$0.5 million. The decreases were offset by increase in trade and other receivables of S\$2.1 million resulting from increase in trade receivables and operating subvention grants and increase in cash and short-term deposits of S\$1.7 million.

## Econ Healthcare (Asia) Limited and its subsidiaries

### Other information required for Half Year Announcement

---

#### *Non-current liabilities*

As at 30 September 2024, the Group's non-current liabilities of S\$30.2 million accounted for 61.7% of total liabilities. Non-current liabilities mainly comprised the following:

- (i) loans and borrowings, which amounted to S\$1.0 million, and is related to funding for the expansion of Group's operations;
- (ii) deferred capital grants, which amounted to S\$2.5 million, and relating to government grants accrued or received for the purpose of equipping and furnishing the nursing homes.
- (iii) provision for restoration costs, which amounted to S\$0.7 million, and is related to the estimated costs of reinstating leased premises to their original state upon termination or expiration of the leases; and
- (iv) lease liabilities, which amounted to S\$26.0 million, being the non-current portion of the future lease payments.

The decrease in non-current liabilities by 11.7% or S\$4.0 million, from S\$34.2 million as at 31 March 2024 to S\$30.2 million as at 30 September 2024 was due to decrease in lease liabilities of S\$3.6 million and decrease in loan and borrowings of S\$0.2 million due to repayments, and decrease in deferred capital grants of S\$0.2 million due to amortisation of the capital grants.

#### *Current liabilities*

As at 30 September 2024, the Group's current liabilities of S\$18.8 million accounted for 38.3% of total liabilities. Current liabilities mainly comprised the following:

- (i) loans and borrowings, which amounted to S\$1.4 million, and is related to funding for the expansion of the Group's operations and general working capital purposes;
- (ii) trade and other payables, which amounted to S\$9.2 million, comprising S\$1.5 million of refundable deposits received from residents, S\$1.1 million of trade payables and S\$5.1 million of accrued operating expenses, S\$0.2 million of deferred grant income and cumulatively accounted for 86.3% of total trade and other payables;
- (iii) lease liabilities, which amounted to S\$6.9 million, being the present value of the future lease payments; and
- (iv) current tax liabilities, which amounted to S\$1.2 million.

Current liabilities increased by S\$7.8 million, from S\$26.6 million as at 31 March 2024 to S\$18.8 million as at 30 September 2024. The decrease was mainly due to completion of the disposal of the discontinued operations liabilities resulting in decrease in liabilities of disposal group classified as held for sale of S\$9.0 million, decrease in loan and borrowings of S\$1.0 million attributable to repayments and current tax liabilities of S\$0.1 million due to tax payments. The decreases were offset by increase in trade and other payables of S\$2.0 million resulting from increase in accrued operating expenses.

## **Econ Healthcare (Asia) Limited and its subsidiaries**

### **Other information required for Half Year Announcement**

---

#### **(C) Statement of cash flows**

Cash flow before changes in working capital for 6M2025 amounted to S\$9.5 million. Net cash generated from operations was S\$9.9 million due to decrease in trade and other receivables of S\$2.2 million and increase in trade and other payables of S\$2.6 million. As a result, net cash generated from operating activities after adjusting for cash paid for tax was S\$9.2 million.

Net cash flow generated from investing activities was S\$0.2 million in 6M2025. Net cash flows used were primarily for purchase of property, plant and equipment amounting to S\$1.0 million. These were offset with the amount refunded for acquisition of subsidiary, net of S\$0.6 million, proceeds of disposal of quoted securities of S\$0.5 million, interest received of S\$50,000, capital grants received of S\$41,000 and dividends received from investments in quoted securities of S\$21,000.

Net cash flow used in financing activities was S\$7.6 million in 6M2025. This was attributable to the repayment of bank borrowings and lease liabilities of S\$1.4 million and S\$3.8 million respectively, interest paid of S\$0.7 million and dividends paid of S\$1.7 million.

Overall, the Group reported a net increase in cash and cash equivalents of S\$1.8 million for 6M2025, ending the period with cash and cash equivalents of S\$17.8 million.

#### **5 Where a forecast, or a prospect statement, has been previously disclosed to shareholders, any variance between it and the actual results**

Not applicable, there has been no forecast or prospect statement disclosed to shareholders previously.

#### **6 A commentary at the date of the announcement of the significant trends and competitive conditions of the industry in which the group operates and any known factors or events that may affect the group in the next reporting period and the next 12 months.**

The nursing home sector in Singapore, Malaysia and China presents encouraging growth prospects as these countries confront growing elderly populations and evolving elder care needs. However, the industry faces broader economic challenges, including labour shortages, inflationary pressures, and shifting family dynamics. Our focus remains on delivering high quality care to our clients by investing in staff capability development, innovation and facility upgrades. Additionally, we are also developing specialised service offerings to meet diverse client needs. In Singapore and Malaysia, the emerging trend of assisted living in the community is gaining traction and reflects a demand for alternative residential elder care options.

## Econ Healthcare (Asia) Limited and its subsidiaries

### Other information required for Half Year Announcement

---

Businesses across all industries are currently experiencing economic pressures and labour challenges. In Singapore, the Ministry of Health Singapore (MOH) has implemented salary guidelines for the community care sector and mandatory minimum salary for healthcare workers effective from July 2024. Similarly, Malaysia's minimum wage increase, set to take effect on 1 February 2025, may have an impact on our business.

Despite these pressures, the robust and growing demand for elder care services in Singapore and Malaysia presents a promising outlook. We are optimistic and will continue to innovate to achieve operational efficiencies and invest to build a future-ready workforce.

#### 7 Dividend

##### (a) Whether an interim (final) ordinary dividend has been declared (recommend); and

Yes. While the Company does not have a fixed dividend policy, the Directors are pleased to recommend an interim dividend for the financial period being reported on, further details as set out below.

##### (b)(i) Amount per share (in cents)

|  | <b>6M2025</b><br><b>S\$'000</b> |
|--|---------------------------------|
| Ordinary shares (tax exempt 1-tier)<br>- Interim (0.48 Singapore cent per share) | 1,276                           |
| Total Interim dividend   | 1,276                           |

##### (b)(ii) Amount per share (in cents) for the previous corresponding period

|  | <b>6M2024</b><br><b>S\$'000</b> |
|--|---------------------------------|
| Ordinary shares (tax exempt 1-tier)<br>- Interim (0.23 Singapore cent per share) | 591                             |
| Total Interim dividend   | 591                             |

**Econ Healthcare (Asia) Limited and its subsidiaries**

**Other information required for Half Year Announcement**

---

- (c) Whether the dividend is before tax, net of tax or tax exempt. If before tax or net of tax, state the tax rate and the country where the dividend is derived. (If the dividend is not taxable in the hands of shareholders, this must be stated).**

Tax exempt one-tier.

- (d) The date the dividend is payable**

17 December 2024

- (e) The date on which Registrable Transfers received by the company (up to 5.00 pm) will be registered before entitlements to the dividend are determined**

Notice is hereby given that the Register of Members and the Transfer Books of the Company will be closed on 3 December 2024 (“Record Date”) for the purpose of determining members’ entitlement to the interim dividend.

Duly completed registrable transfers received by the Company’s Share Registrar, In.Corp Corporate Services Pte. Ltd., 30 Cecil Street #19-08 Prudential Tower Singapore 049712, up to 5.00 p.m. on 3 December 2024 will be registered before entitlements to the dividend are determined.

- (f) If no dividend has been declared (recommended), a statement to that effect and the reason(s) for the decision.**

Not applicable, the Group intends to declare an interim dividend in respect of 6M2025.

**Econ Healthcare (Asia) Limited and its subsidiaries**

**Other information required for Half Year Announcement**

- 8 If the Group has obtained a general mandate from shareholders for IPTs, the aggregate value of such transactions as required under Rule 920(1)(a)(ii). If no IPT mandate has been obtained, a statement to that effect.**

| Name of Interested Person   | Aggregate value (\$'000) of all IPTs during the financial period under review | Aggregate value of all IPTs conducted during the financial year under review under shareholders' mandate pursuant to Rule 920 (excluding transactions less than S\$100,000) |
|---|---|---|
| (1) Econ Healthcare Pte Ltd<br>- Lease of 3 nursing homes:<br>(a) ECON Medicare Centre and Nursing Home – Braddell<br>(b) ECON Medicare Centre and Nursing Home – Choa Chu Kang<br>(c) ECON Medicare Centre and Nursing Home – Upper East Coast       | 926   | Not applicable - the Group does not have a shareholders' mandate under Rule 920   |
| (2) Econ Medicare Centre Holdings Pte Ltd<br>(a) Lease of ECON Medicare Centre and Nursing Home – Recreation Road<br>(b) Lease of staff quarters at Recreation Road<br>(c) Sublease agreement for Hexacube office<br>(d) Accounting service agreement | 191   |   |
| (3) Econ Healthcare Pte Ltd<br>(a) Sub lease agreement for Chai Chee Nursing Home   | 352   |   |
| (4) Ekang International Holdings Pte. Ltd.<br>(a) Lease of Hexacube office  | 259   |   |
| (5) TMI Technologies Pte Ltd<br>(a) Sub lease arrangement for Hexacube office<br>(b) Accounting service agreement   | 6   |   |
| (6) West Point Hospital (Singapore) Pte. Ltd.<br>(a) Provision of vehicles on-site for emergency ambulance services and medical transport services<br>(b) Provision of ambulance crew support services  | 62  |   |

## Econ Healthcare (Asia) Limited and its subsidiaries

### Other information required for Half Year Announcement

---

#### 9 Negative confirmation pursuant to Rule 705(5).

The Board of Directors of the Company hereby confirm that, to the best of their knowledge, nothing has come to the attention of the Board of Directors which may render the unaudited interim condensed financial statements for the period ended 30 September 2024 to be false or misleading in any material aspect.

#### 10 Confirmation that the issuer has procured undertakings from all its directors and executive officers (in the format set out in Appendix 7H) under Rule 720(1).

The Company has procured undertakings from all its Directors and Executive Officers (in the format set out in Appendix 7H) under Rule 720(1) of the of the SGX-ST Listing Manual Section B: Rules of Catalist.

#### 11 Disclosure of person occupying a managerial position in the issuer or any of its principal subsidiaries who is a relative of a director or chief executive officer or substantial shareholder of the issuer pursuant to Rule 704(10) in the format below. If there are no such persons, the issuer must make an appropriate negative statement.

| Name         | Age | Family relationship with any director, CEO and/or substantial shareholder   | Current position and duties, and the year the position was first held | Details of changes in duties and position held, if any, during the year                     |
|--------------|-----|---|---|---|
| Koh Hin Ling | 70  | Wife of Ong Chu Poh (Executive Chairman and Group Chief Executive Officer); and<br>Mother of Ong Hui Ming (Executive Director and Deputy Chief Executive Officer) | Director of TCM, TCM practitioner, with effect from 1994              | Resigned as Director of the Group's principal subsidiaries, with effect from 1 October 2024 |



## Econ Healthcare (Asia) Limited and its subsidiaries

### Other information required for Half Year Announcement

---

#### 12 Use of IPO proceeds

Pursuant to the Company's initial public offering on 19 April 2021, the Company received gross proceeds of S\$14.0 million from the placement of new shares. As at the date of this announcement, the net proceeds have been utilised as follows:

|  | Revised balance<br>(as disclosed in<br>announcement on<br>8 June 2023) <sup>(1)</sup> | Amount utilised as<br>at the date of this<br>condensed<br>financial<br>statements <sup>(2)</sup> | Balance at the<br>date of this<br>condensed<br>financial<br>statements |
|--|---|--|--|
|  | S\$'000   | S\$'000  | S\$'000  |
| Expansion plans in Singapore as well as overseas through, among others, joint ventures, strategic collaborations, mergers and acquisitions, or investments; together with upgrading of existing medicare centres and nursing homes and other facilities, including equipment and IT infrastructure | 7,947   | 7,432  | 515  |
| General corporate and working capital purposes   | 2,070   | –  | 2,070  |
| Total  | 10,017  | 7,432  | 2,585  |

<sup>(1)</sup> As announced on 8 June 2023, the Company announced that net proceeds of S\$4.0 million had been utilised and that the use of proceeds would be revised to allocate the unutilised balance proceeds of S\$10.0 million to the consolidated use of expansion plans and upgrading plans of the Group for existing centres and facilities.

<sup>(2)</sup> The amount utilised as at the date of this announcement refer to the expenses billed to date and amount paid up to date.

#### BY ORDER OF THE BOARD

Ong Chu Poh

Executive Chairman and Group Chief Executive Officer

12 November 2024